Cargando…
Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia
Decitabine is a hydrophilic drug that acts by hypomethylating DNA. Decitabine is used in Europe for the treatment of acute myeloid leukemia (AML) in patients aged ≥65 years. However, it can only be administered intravenously due to very low oral bioavailability and a large distribution volume. Oral...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703174/ https://www.ncbi.nlm.nih.gov/pubmed/29200853 http://dx.doi.org/10.2147/IJN.S147659 |